Understanding MFN Pricing: Key Considerations for Pharma Manufacturers

Recent developments surrounding Most-Favored-Nation (MFN) pricing continue to reshape discussions around pricing and access strategy across the pharmaceutical industry.

In a recent interview with Pharmaceutical Executive, Alan Crowther, General Manager, Global Pricing & Access at EVERSANA, shared his perspective on what the latest MFN updates could mean for manufacturers, particularly those with limited portfolios, significant U.S. exposure or evolving global launch plans.

What is MFN Pricing in Pharma? Moving Beyond a Single Policy

One of the key themes highlighted by Crowther is that MFN should not be viewed as a single pricing program. Rather, it consists of multiple frameworks, each with different qualification requirements, pricing calculations and potential implications for manufacturers.

As companies evaluate their exposure, factors such as channel mix, payer mix, international pricing strategies and future indications can significantly influence risk and opportunity. For many teams, understanding those variables requires extensive scenario modeling and long-term planning.

How MFN Pricing Impacts Emerging and Mid-Sized Biopharma

For organizations with one or two commercial assets, pricing decisions may have an outsized impact on future growth.

Global Launch Sequencing and Reference Pricing

According to Crowther, MFN-related decisions can affect not only U.S. revenue, but also broader launch sequencing and global pricing strategies. Companies may face difficult tradeoffs when determining how and where to launch products, particularly when considering international reference pricing implications.

Long-Term Pricing Strategy: Navigating MFN, IRA, and Government Regulations

MFN does not operate in isolation. Manufacturers must also consider interactions with other pricing and reimbursement mechanisms, including IRA negotiations, Medicaid rebate calculations and broader government pricing programs.

As regulatory environments evolve, pricing and access leaders will need to balance immediate commercial considerations with future uncertainty.

The result is a planning environment that demands sophisticated modeling, cross-functional alignment and a clear understanding of the potential downstream consequences of pricing decisions.

For manufacturers navigating today’s pricing landscape, the challenge is no longer simply understanding individual policies. Success increasingly depends on understanding how multiple pricing, reimbursement and market access dynamics interact over time.

Learn more about NAVLIN and EVERSANA’s Global Pricing & Access capabilities